Title: Biomarkers as Key Drivers of Drug Development in Gene Therapy

Biography:

Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and medical affairs. Dr Segurado is the Chief Medical Officer for ASC Therapeutics, and formerly held CMO positions for Symvivo, Myriad Genetics-Crescendo and CellMax Life, as well as roles such as Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie. Dr Segurado is a senior medical leader experienced in matrixed, line management and consulting for biotechs, midsize and large pharma companies. He has extensive expertise in gene therapy (ASC, AveXis, UCLA Ventures, UniQure, Symvivo), immuno-oncology (Amgen, AstraZeneca, Bellicum, Jazz), immuno-therapy (Bristol-Myers Squibb, Macrogenics, TriSalus), genomics (Freenome, Myriad) and protein/cell diagnostics (Abbott, BD, Crescendo), predominantly focused on oncology, hematology and autoimmunity, including personalized medicine, molecular and cellular biomarkers. Dr Segurado holds a tenured Professorship of Immunology at the University of Leon, Spain, currently on leave. He received his PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain. Prior to this, he was an associate professor at the Faculties of Medicine in the University of Munich, Germany, and University Complutense of Madrid, Spain. Dr Segurado has authored and co-authored over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, as well as books and medical articles and is a member of several scientific and medical societies, including ASCO, ASH, ESMO, AACR and SITC.

Abstract